RLT-PSMA

FDA Approves New Indication for Illuccix to Include Patient Selection
The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Illuccix, Telix Pharmaceuticals’ prostate cancer imaging kit. The sNDA will enable the use of Illuccix to aid in the selection of patients with metastatic prostate cancer for whom radioligand therapy is indicated. After radiolabeling with gallium (68Ga), Illuccix is used for the preparation of 68Ga gozetotide injections for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer who have suspected metastasis and are suitable for initial definitive therapy, or who have suspected recurrence ...
Advertisement

Latest News

Advertisement

Expert Interviews

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer
Prostate Cancer

Conference Coverage

Advertisement
Roundtables

Advertisement